CCM
NKTR icon

Covington Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Covington Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6
Closed -$2K – 773
2020
Q2 		$2K Hold
6
– – ﹤0.01% 729
2020
Q1 		$2K Hold
6
– – ﹤0.01% 725
2019
Q4 		$2K Hold
6
– – ﹤0.01% 857
2019
Q3 		$2K Hold
6
– – ﹤0.01% 777
2019
Q2 		$3K Hold
6
– – ﹤0.01% 745
2019
Q1 		$3K Hold
6
– – ﹤0.01% 699
2018
Q4 		$3K Hold
6
– – ﹤0.01% 705
2018
Q3 		$5K Hold
6
– – ﹤0.01% 647
2018
Q2 		$4K Hold
6
– – ﹤0.01% 671
2018
Q1 		$10K Buy
+6
New +$7.73K ﹤0.01% 638

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Covington Capital Management's NKTR Position: Q3 2020 in Review

Covington Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 6 shares — an estimated $2K sold.

Covington Capital Management first reported a position in NKTR in Q1 2018 and held it in 10 quarters. The position peaked at $10K in Q1 2018. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Covington Capital Management reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Covington Capital Management sold 6 Nektar Therapeutics shares in Q3 2020, an estimated $2K.
  • Covington Capital Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 10 quarters.
  • Covington Capital Management's Nektar Therapeutics position peaked at $10K in Q1 2018.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Covington Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.